• Philadelphia, PA (March 19, 2018) – Oncoceutics, Inc. announced that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2018 annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois, on April 14th to April 18th.

    These abstracts highlight the unique way that ONC201 engages the dopamine receptor, leading to downstream direct anti-tumor and immune oncology effects, which are especially pronounced in tumors with dopamine pathway dysregulation. These tumors include H3 K27M mutant high grade gliomas and other cancers, where ONC201 is now in advanced clinical trials.

    Additionally, the abstracts showcase the continued preclinical advancement of other members of the imipridone family. ONC212 will be featured in an oral presentation highlighting its ability to treat aggressive leukemias as a single agent, and effectively synergize with other anti-leukemic agents, specifically BCL-2 inhibitors, due to its unique GPCR target. ONC206 demonstrates parallel characteristics with ONC201, while also being differentiated by a unique binding profile.

    The abstracts are listed below and categorized by topic: ONC201 clinical translation; ONC201 preclinical single agent and combinatorial activity; and analogs (ONC206 and ONC212). All poster presentations will be in McCormick Place South, Exhibit Hall A, and the oral presentation of ONC212 will take place in Room S102 – McCormick Place South (Level 1) at the times described below.

     

    ONC201 Clinical Translation:

    1. Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201

    April 17, 2018, 8:00 AM

     

    1. ONC201 induction of apoptosis in hPheo1 cell line supports use of this oral agent in ongoing phase 2 clinical trial against neuroendocrine tumors

    April 17, 2018, 1:00 PM

     

    1. Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients

    April 18, 2018, 8:00 AM

     

    ONC201 Preclinical Single Agent and Combinatorial Activity

    1. Treatment and signaling contexts for the application of the imipridone ONC201 to prostate cancer cells

    April 15, 2018, 1:00 PM

     

    LB-082. ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation

    April 16, 2018, 8:00 AM – 12:00 PM

     

    1. Synergistic antitumor effect of ONC201 in combination with radiation therapy

    April 16, 2018, 1:00 PM

     

    1. Combination ONC201 and radiation therapy in the treatment of breast cancer

    April 16, 2018, 1:00 PM

     

    Analogs (ONC206 and ONC212):

    1. Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206

    April 17, 2018, 1:00 PM

     

    1. The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132

    April 17, 2018, 3:35 PM – Oral Presentation

     

    About Oncoceutics

    Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received more than $7 million in grants over the last two years, including grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center.  The company has established a robust intellectual property position, including several issued patents.

     

    Contact press@oncoceutics.com for more information.

Photostream